Cumberland Pharmaceuticals (CPIX) AI Stock Analysis

• Market Cap: $82.44M
• Dividend Yield: N/A
• Average Volume (3M): 35.05K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.33
• Revenue Growth: 5.82%
• EPS Growth: 59.86%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 55
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.08
• Shares Outstanding: 14,961,137
• 10 Day Avg. Volume: 39,593
• 30 Day Avg. Volume: 35,053
• PEG Ratio: -2.20
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.14
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 0.22
• Enterprise Value/Gross Profit: 1.06
• Enterprise Value/Ebitda: -6.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 63 Neutral
• Price Target: $6.00 ▲(2.39%Upside)

Cumberland Pharmaceuticals scores moderately due to significant revenue growth and positive earnings call sentiment, reflecting recent financial improvements and strategic market expansions. However, challenges remain with ongoing profitability issues and a negative P/E ratio, which impact the overall valuation and financial performance.

Cumberland Pharmaceuticals Business Overview & Revenue Model

Company Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

How the Company Makes Money

Cumberland Pharmaceuticals generates revenue through the sale of its proprietary pharmaceutical products. The company primarily sells its products to wholesalers, distributors, and hospital purchasing organizations, which then distribute them to healthcare facilities and pharmacies. Cumberland's revenue model relies significantly on the commercialization and market penetration of its existing product portfolio, as well as the successful development and launch of new products. Additionally, strategic partnerships and licensing agreements for product distribution and development play a crucial role in enhancing Cumberland's market reach and contributing to its earnings.

Cumberland Pharmaceuticals Financial Statement Overview

Summary

Cumberland Pharmaceuticals faces significant challenges with declining revenues and profitability, impacting its overall financial health. The balance sheet shows manageable leverage, but declining equity ratio and negative returns on equity highlight the need for improvement. However, the company generates positive free cash flow, which should support near-term liquidity needs.

Income Statement

The company's income statement shows a declining trend in total revenue from 2022 to the TTM period, with a noticeable decrease in profitability. The gross profit margin is relatively stable but the net profit margin is negative due to consistent net losses, indicating challenges in managing expenses. EBIT and EBITDA margins are also under pressure, reflecting operational inefficiencies.

Balance Sheet

The balance sheet indicates moderate financial stability, with a debt-to-equity ratio that suggests manageable leverage. However, the company's equity ratio has been declining, indicating reduced financial cushion. Return on equity remains negative, reflecting ongoing net losses. Despite these challenges, the company maintains a reasonable level of cash and equivalents.

Cash Flow

The cash flow statement reflects a mixed performance, with positive free cash flow in the TTM period providing some financial flexibility. However, the volatile operating cash flow to net income ratio suggests inconsistency in cash generation relative to net earnings. The company has been able to generate positive free cash flow, which is a positive sign.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
41.08M	37.87M	39.55M	42.01M	35.99M	37.44M
	Gross Profit
32.01M	26.38M	33.49M	32.89M	27.17M	28.79M
	EBIT
-3.22M	-7.10M	-6.21M	-5.70M	-7.68M	-6.38M
	EBITDA
1.81M	182.42K	153.32K	332.92K	-857.83K	-1.56M
	Net Income Common Stockholders
-3.28M	-6.48M	-6.28M	-5.65M	-5.60M	-6.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
15.11M	17.96M	18.32M	19.76M	27.04M	24.75M
	Total Assets
69.94M	75.58M	81.78M	92.93M	84.46M	96.46M
	Total Debt
10.44M	20.57M	18.43M	20.96M	16.06M	17.08M
	Net Debt
-4.67M	2.61M	106.86K	1.20M	-10.98M	-7.68M
	Total Liabilities
41.60M	53.04M	52.52M	56.95M	41.86M	49.59M
	Stockholders Equity
28.66M	22.85M	29.60M	36.27M	42.81M	46.99M
Cash Flow		Free Cash Flow
5.34M	-791.90K	5.64M	6.38M	5.99M	3.30M
	Operating Cash Flow
5.42M	-612.19K	6.09M	8.45M	6.34M	5.42M
	Investing Cash Flow
-1.11M	57.84B	-105.69K	-13.67M	-501.89K	-1.76M
	Financing Cash Flow
-7.75M	196.90B	-7.42M	-2.06M	-3.55M	-7.12M

Cumberland Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPIX, the sentiment is Positive. The current price of 5.86 is above the 20-day moving average (MA) of 5.35, above the 50-day MA of 4.87, and above the 200-day MA of 3.10, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 55.33 is Neutral, neither overbought nor oversold. The STOCH value of 60.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CPIX.

Cumberland Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPIX	63 Neutral	$82.44M	―	-11.67%	―	5.82%	59.86%
ICAD	60 Neutral	$108.51M	―	-16.53%	―	-4.15%	3.49%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
RPTX	53 Neutral	$61.76M	―	-71.64%	―	-98.90%	-177.17%
CRBP	43 Neutral	$113.07M	―	-44.89%	―	―	64.71%
ATNM	41 Neutral	$51.79M	―	-130.87%	―	-100.00%	30.65%
CYCC	38 Underperform	$6.21M	―	-1949.77%	―	-89.76%	80.28%